A Pivotal Phase III Study Of MIN-101 In Schizophrenic Patients With Negative Symptoms

Trial Profile

A Pivotal Phase III Study Of MIN-101 In Schizophrenic Patients With Negative Symptoms

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs MIN 101 (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Minerva Neurosciences
  • Most Recent Events

    • 06 Nov 2017 According to a Minerva Neurosciences media release, the final protocol for this trial has been submitted to the Investigational New Drug application (IND), and the first Institutional Review Board (IRB) approval has been received for the study in the U.S.
    • 06 Nov 2017 According to a Minerva Neurosciences media release, status changed from planning to not yet recruiting.
    • 06 Nov 2017 According to a Minerva Neurosciences media release, the company is on schedule to initiate this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top